SPDR S&P Biotech ETF (NYSEARCA:XBI) Shares Bought by Hillcrest Wealth Advisors NY LLC

Hillcrest Wealth Advisors NY LLC grew its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 37.5% in the second quarter, according to its most recent filing with the SEC. The firm owned 4,400 shares of the exchange traded fund’s stock after acquiring an additional 1,200 shares during the quarter. Hillcrest Wealth Advisors NY LLC’s holdings in SPDR S&P Biotech ETF were worth $386,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in XBI. JPMorgan Chase & Co. raised its stake in shares of SPDR S&P Biotech ETF by 56.6% in the 1st quarter. JPMorgan Chase & Co. now owns 4,761,913 shares of the exchange traded fund’s stock worth $431,143,000 after buying an additional 1,720,255 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd raised its position in shares of SPDR S&P Biotech ETF by 55.5% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 933,000 shares of the exchange traded fund’s stock worth $84,474,000 after purchasing an additional 333,000 shares during the period. Janney Capital Management LLC acquired a new stake in shares of SPDR S&P Biotech ETF during the first quarter worth $14,297,000. Nomura Asset Management Co. Ltd. acquired a new stake in shares of SPDR S&P Biotech ETF during the first quarter worth $5,985,000. Finally, Parkside Investments LLC raised its position in shares of SPDR S&P Biotech ETF by 314.3% during the second quarter. Parkside Investments LLC now owns 62,210 shares of the exchange traded fund’s stock worth $5,456,000 after purchasing an additional 47,195 shares during the period.

Shares of SPDR S&P Biotech ETF stock traded down $1.74 on Friday, reaching $79.88. 3,137,216 shares of the company were exchanged, compared to its average volume of 4,662,777. The stock has a fifty day moving average price of $84.81 and a 200-day moving average price of $85.90. SPDR S&P Biotech ETF has a fifty-two week low of $64.38 and a fifty-two week high of $100.70.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Further Reading: Gap Down Stocks

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.